Jacob Stuckey

Company: Flare Therapeutics

Job title: Vice President - Biochemistry & Chemical Biology

Seminars:

Insights into Covalent Drug Discovery from FX-909 11:30 am

FX-909 is a potent and selective inverse agonist of PPARG currently being explored in muscle-invasive luminal urothelial cancer FX-909’s selectivity and in vivo properties are derived from the “context-dependent reactivity” exhibited by its unique warhead Mechanistic investigations into covalent capture of PPARG were critical for the design and discovery of FX-909 and have also revealed…Read more

day: Day One